Details of the Drug Combination

General Information of Drug Combination (ID: DCAGH8W)

Drug Combination Name

Iodixanol Bivalirudin

Indication

Disease Entry	Status	REF
Coronary Artery Disease	Phase 4	[1]

Component Drugs

Iodixanol DMA2Q8L

Bivalirudin DMECRX1

N.A.

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Iodixanol

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Approved	[2]

Indication(s) of Bivalirudin

Disease Entry	ICD 11	Status	REF
Thrombocytopenia	3B64	Approved	[3]

Bivalirudin Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[4]
Trypanosoma Trypanothione reductase (Trypano TPR)	TTRTKPV	TYTR_TRYBB	Inhibitor	[5]
------------------------------------------------------------------------------------

Bivalirudin Interacts with 4 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Decreases Expression	[6]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[7]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Decreases Activity	[8]
Proteinase-activated receptor 4 (F2RL3)	OTUNAKDB	PAR4_HUMAN	Decreases Activity	[8]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01848899) Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6470).
4	New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
5	8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8.
6	Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31.
7	The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis. 2005 Sep;16(6):401-5. doi: 10.1097/00019501-200509000-00010.
8	Bivalirudin: a new promising direct antithrombin. Indian Heart J. 2007 May-Jun;59(3):288-94.